Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) EBIT (2020 - 2025)

Historic EBIT for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to -$7.7 million.

  • Bolt Biotherapeutics' EBIT rose 5315.33% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.9 million, marking a year-over-year increase of 3946.61%. This contributed to the annual value of -$73.0 million for FY2024, which is 413.15% up from last year.
  • As of Q3 2025, Bolt Biotherapeutics' EBIT stood at -$7.7 million, which was up 5315.33% from -$9.2 million recorded in Q2 2025.
  • Bolt Biotherapeutics' EBIT's 5-year high stood at -$7.7 million during Q3 2025, with a 5-year trough of -$27.1 million in Q4 2021.
  • Moreover, its 5-year median value for EBIT was -$19.8 million (2023), whereas its average is -$19.1 million.
  • Per our database at Business Quant, Bolt Biotherapeutics' EBIT tumbled by 11387.04% in 2021 and then skyrocketed by 5924.24% in 2025.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' EBIT stood at -$27.1 million in 2021, then increased by 22.29% to -$21.0 million in 2022, then grew by 6.06% to -$19.8 million in 2023, then grew by 14.42% to -$16.9 million in 2024, then skyrocketed by 54.46% to -$7.7 million in 2025.
  • Its EBIT was -$7.7 million in Q3 2025, compared to -$9.2 million in Q2 2025 and -$12.1 million in Q1 2025.